Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (5): 971-974. doi: 10.19723/j.issn.1671-167X.2020.05.030

Previous Articles     Next Articles

Concordant point mutation of ETS-related gene (ERG) in tumor tissues from a synchronous multiple primary lung cancer: A case report

Yi BAO1,2,(),Juan-fen MO2   

  1. 1. Department of Oncology, The Second Hospital of Jiaxing, Jiaxing 314000, Zhejiang, China
    2. Key Laboratory, The Second Hospital of Jiaxing, Jiaxing 314000, Zhejiang, China
  • Received:2018-10-16 Online:2020-10-18 Published:2020-10-15
  • Contact: Yi BAO E-mail:ybao2011@gmail.com
  • Supported by:
    Science and Technology Bureau of Jiaxing(2016AY23054);Health Bureau of Zhejiang Province(2016KYB292)

RICH HTML

  

Abstract:

The rearrangement of the gene encoding the transcription factor ETS-related gene (ERG) is thought to play a key role in the development of prostate cancer. However, the studies on the ERG mutations have been rarely reported in non-small cell lung carcinoma (NSCLC). Here, we reported genetic features regarding a case of a 68-year-old male patient who presented the primary synchronous multiple tumor lesions in the separated lungs. The patient was hospitalized due to the presence of tumor lesions at the right and left lungs revealed by a chest computerized tomography (CT) scan. After conducting lobectomies at the both lungs, the tumor nodules were all removed, and the histological analysis suggested adenocarcinoma at the both tumor lesions. The patient was diagnosed with synchronous multiple primary lung cancer (SMPLC) based on Martini-Melamed criteria and American College of Chest Physicians practice guidelines. An exome analysis of 315 genes in the two tumor lesions and a non-tumor lesion was conducted by using Illumina Nextseq500 platform from each tumor region to decipher a potential evolutional progress of SMPLC. Single or pair-end reads were first mapped to a human genome reference and filtered based on the mapping quality score. The read depth was ≥ 1 000× and the depth of coverage was 95%. The data revealed a discordant epidermal growth factor receptor (EGFR) from the separate lungs; additionally, a high frequency of point mutation on exon 9 H310P of the ERG gene was detected at the both sites of the tumor lesions. This case showed that a potential role of the molecular features analysis from each tumor lesion might contribute to the understanding of the evolutional development of SMPLC. This study suggests that the same environment may contribute certain gene(s) mutations in the same sites in the early stages of polyclonal tumor origins; meanwhile the extensive studies on these genes may help us understand the evolution and progress of tumor clones.

Key words: Lung neoplasms, Neoplasms, multiple primary, ETS-related gene, Mutation, High-throughput nucleotide sequencing

CLC Number: 

  • R734.2

Figure 1

The images of chest computed tomography (CT) before surgeries A, the arrow showed a size of 2.0 cm×2.0 cm lesion with irregular high density shadow at the upper lobe of right lung; B, the arrow showed a size of 1.4 cm×3.3 cm with ground glass nodule in the bottom lobe of left lung. "

Table 1

Comparison of somatic cell gene mutation with mutaton frequency ≥5% between the two separate tumor lesions"

Items Tumor nodule Gene Chromosome location Gene mutation Density Mutation frequency
Discordant (≥5%) Left side EGFR 7p11.2 exon21,c.2573T>G,p.L858R 1 844 15%(290/1 884)
ACVR1B 12q13.13 exon2,c.106T>A,p.C36S 554 9%(48/554)
GRIN2A 16p13.2 exon11,c.2326G>A,p.D776N 647 9% (56/647)
ATR 3q23 exon47,c.7912C>T,p.L2638F 483 7% (32/483)
EGFR 7p11.2 exon19,c.2240T>C,p.L747S 2 906 7% (207/2 906)
CBFR 16q22.1 exon5,c.481C>T,p.R161W 951 5% (48/951)
NF1 17q11.2 exon33,c.4462C>T,p.R1488C 775 5% (35/775)
NOTCH2 1p12 exon34,c.7153A>C,p.T2385P 914 5% (44/914)
Right side ARID2 12q12 exon5,c.539G>A,p.C180Y 588 6%(34/588)
ARID2 12q12 exon15,c.1960C>G,p.P654A 1 058 5% (48/1 058)
Concordant(≥5%) Left side ERG 21q22.2 exon9,c.929A>C,p.H310P 637 9% (60/637)
Right side ERG 21q22.2 exon9,c.929A>C,p.H310P 929 8% (74/929)

Figure 2

The mutation of ERG was analyzed from the TCGA non-small-cell lung carcinoma samples by using the cBioportal data analysis platform"

Figure 3

The correlation of ERG mutation and overall survival was analyzed from the TCGA non-small-cell lung carcinoma samples by using the cBioportal data analysis platform"

[1] Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer[J]. Nat Rev Cancer, 2008,8(7):497-511.
doi: 10.1038/nrc2402 pmid: 18563191
[2] Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer[J]. Cancer Cell, 2011,19(5):664-678.
doi: 10.1016/j.ccr.2011.04.010
[3] Wang X, Qiao Y, Asangani IA, et al. Development of peptidomimetic inhibitors of the ERG gene gusion product in prostate cancer[J]. Cancer Cell, 2017,31(4):532-548.
doi: 10.1016/j.ccell.2017.02.017 pmid: 28344039
[4] Martini N, Melamed MR. Multiple primary lung cancers[J]. J Thorac Cardiovasc Surg, 1975,70(4):606-612.
pmid: 170482
[5] Kozower BD, Larner JM, Detterbeck FC. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013,143(5 Suppl):e369S-e399S.
doi: 10.1378/chest.12-2362 pmid: 23649447
[6] Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin[J]. Cancer, 1953,6(5):963-968.
doi: 10.1002/1097-0142(195309)6:5<963::aid-cncr2820060515>3.0.co;2-q pmid: 13094644
[7] Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma[J]. Nature, 2014,511(7511):543-550.
doi: 10.1038/nature13385
[8] Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer[J]. N Engl J Med, 2017,376(22):2109-2121.
doi: 10.1056/NEJMoa1616288 pmid: 28445112
[9] Adamo P, Ladomery MR. The oncogene ERG: A key factor in prostate cancer[J]. Oncogene, 2016,35(4):403-414.
doi: 10.1038/onc.2015.109 pmid: 25915839
[10] Ida K, Kobayashi S, Taki T, et al. EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing’s sarcoma and primitive neuroectodermal tumor[J]. Int J Cancer, 1995,63(4):500-504.
doi: 10.1002/ijc.2910630407 pmid: 7591257
[11] Nagai N, Ohguchi H, Nakaki R, et al. Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition[J]. PLoS Genet, 2018,14(11):e1007826.
doi: 10.1371/journal.pgen.1007826 pmid: 30500808
[1] Zhicun LI, Tianyu WU, Lei LIANG, Yu FAN, Yisen MENG, Qian ZHANG. Risk factors analysis and nomogram model construction of postoperative pathological upgrade of prostate cancer patients with single core positive biopsy [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 896-901.
[2] Yuxuan TIAN,Mingjian RUAN,Yi LIU,Derun LI,Jingyun WU,Qi SHEN,Yu FAN,Jie JIN. Predictive effect of the dual-parametric MRI modified maximum diameter of the lesions with PI-RADS 4 and 5 on the clinically significant prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 567-574.
[3] Kaifeng YAO,Mingjian RUAN,Derun LI,Yuxuan TIAN,Yuke CHEN,Yu FAN,Yi LIU. Diagnostic efficacy of targeted biopsy combined with regional systematic biopsy in prostate cancer in patients with PI-RADS 4-5 [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 575-581.
[4] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[5] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[6] Yi LIU,Chang-wei YUAN,Jing-yun WU,Qi SHEN,Jiang-xi XIAO,Zheng ZHAO,Xiao-ying WANG,Xue-song LI,Zhi-song HE,Li-qun ZHOU. Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5 [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 812-817.
[7] Min QIU,You-long ZONG,Bin-shuai WANG,Bin YANG,Chu-xiao XU,Zheng-hui SUN,Min LU,Lei ZHAO,Jian LU,Cheng LIU,Xiao-jun TIAN,Lu-lin MA. Treatment outcome of laparoscopic partial nephrectomy in patients with renal tumors of moderate to high complexity [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 833-837.
[8] Chang-wei YUAN,De-run LI,Zhi-hua LI,Yi LIU,Gang-zhi SHAN,Xue-song LI,Li-qun ZHOU. Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 838-842.
[9] Hui-li LIU,Yan-han LV,Xiao-xiao WANG,Min LI. Factors influencing the chronic post-surgical pain after laparoscopic surgery for elderly patients with urinary tract tumors [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 851-856.
[10] Zhong CAO,Hong-bing CEN,Jian-hong ZHAO,Jun MEI,Ling-zhi QIN,Wei LIAO,Qi-lin AO. Expression and significance of INSM1 and SOX11 in pancreatic neuroendocrine tumor and solid pseudopapillary neoplasm [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 575-581.
[11] Jian-xun MA,You-chen XIA,Bi LI,Hong-mei ZHAO,Yu-tao LEI,Xi BU. Choice of immediate breast reconstructive methods after modified radical mastectomy [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 612-618.
[12] Yu-xiao WU,Yi-fan KANG,Qian-ying MAO,Zi-meng LI,Xiao-feng SHAN,Zhi-gang CAI. Application of methylene blue near-infrared fluorescence imaging for oral sentinel lymph node mapping in rats [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 684-688.
[13] Shang XIE,Zhi-gang CAI,Xiao-feng SHAN. Application value of whole exon sequencing and immune related indicators in the precision treatment of oral squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 697-701.
[14] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[15] Yun-jing ZHANG,Li-ying QIAO,Meng QI,Ying YAN,Wei-wei KANG,Guo-zhen LIU,Ming-yuan WANG,Yun-feng XI,Sheng-feng WANG. Development and validation of risk prediction model for new-onset cardiovascular diseases among breast cancer patients: Based on regional medical data of Inner Mongolia [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 471-479.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!